Review



part conditioned medium  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Miltenyi Biotec part conditioned medium
    Induction of LFs and anti-RABV-G IgG production by SAM-LNP1 in human LF chips (A) Schematic of the LF Chip created with monocytes and <t>conditioned</t> medium from the intramuscular vaccination-mimicking module created with BioRender.com . (B) Representative 3D confocal microscopic stacks showing pseudo-colored follicles (blue) and cell nuclei (green) present within extracellular matrix (ECM) gels cultured for 4 days within a perfused LF Chip when vaccinated with SAM-LNP1 in the absence or presence of IL-2 and IL-4 (SAM-LNP1 + IL-2&IL-4); scale bars, 100 μm. (C) Quantification of the number (left) and size (right) of LFs in LF chips of one donor based on immunostaining followed by confocal imaging. Each data point represents one field of view (left) or an individual follicle (right); 2 independent chips were analyzed per condition. (D) Anti-RABV-G IgG levels in effluents of no treatment LF chips or chips vaccinated with or without IL-2 and IL-4 and cultured for 14 days were detected using a cell-based assay; 3–4 independent chips were analyzed per condition. (E) Quantification of the number (left) and size (right) of LFs in LF chips from four different donors, with each color representing a different donor. Each data point corresponds to one field of view (left) or an individual follicle (right). (F) Anti-RABV-G IgG levels in effluents of LF chips. Each data point represents one chip, with different symbols indicating chips from three independent donors. (G) Anti-RABV-G IgG levels in effluents of LF chips seeded with naive B + bulk T + monocyte mixture. Each data point represents one chip, with different symbols indicating chips from three independent donors. (H) Heatmap showing average log2 fold changes in cytokine levels in the effluents of three LF chips created using bulk lymphocytes from donors whose prior exposure to rabies was unknown, measured using a Luminex Multiplex Assay at various time points (4, 7, 15, 22, and 28 days post-vaccination) compared to the average levels of each cytokine found at day 1. Representative results from one donor are shown in (B)–(D) and (H), with similar outcomes observed in two donors. Data shown are mean ± SD; (C, left; D; and E) one way ANOVA test followed by Tukey’s multiple comparisons test, (C, right; and E) Mann-Whitney U test, (F and G) Welch’s t test.
    Part Conditioned Medium, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 133 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+2/Human+IL-2+IS%2C+research+grade/pmc13314794-290-18-34
    Average 96 stars, based on 133 article reviews
    part conditioned medium - by Bioz Stars, 2026-09
    96/100 stars

    Images

    1) Product Images from "In vitro recapitulation of intramuscular mRNA vaccination with naive and recall antigens using a human lymphoid follicle chip platform"

    Article Title: In vitro recapitulation of intramuscular mRNA vaccination with naive and recall antigens using a human lymphoid follicle chip platform

    Journal: iScience

    doi: 10.1016/j.isci.2026.116416

    Induction of LFs and anti-RABV-G IgG production by SAM-LNP1 in human LF chips (A) Schematic of the LF Chip created with monocytes and conditioned medium from the intramuscular vaccination-mimicking module created with BioRender.com . (B) Representative 3D confocal microscopic stacks showing pseudo-colored follicles (blue) and cell nuclei (green) present within extracellular matrix (ECM) gels cultured for 4 days within a perfused LF Chip when vaccinated with SAM-LNP1 in the absence or presence of IL-2 and IL-4 (SAM-LNP1 + IL-2&IL-4); scale bars, 100 μm. (C) Quantification of the number (left) and size (right) of LFs in LF chips of one donor based on immunostaining followed by confocal imaging. Each data point represents one field of view (left) or an individual follicle (right); 2 independent chips were analyzed per condition. (D) Anti-RABV-G IgG levels in effluents of no treatment LF chips or chips vaccinated with or without IL-2 and IL-4 and cultured for 14 days were detected using a cell-based assay; 3–4 independent chips were analyzed per condition. (E) Quantification of the number (left) and size (right) of LFs in LF chips from four different donors, with each color representing a different donor. Each data point corresponds to one field of view (left) or an individual follicle (right). (F) Anti-RABV-G IgG levels in effluents of LF chips. Each data point represents one chip, with different symbols indicating chips from three independent donors. (G) Anti-RABV-G IgG levels in effluents of LF chips seeded with naive B + bulk T + monocyte mixture. Each data point represents one chip, with different symbols indicating chips from three independent donors. (H) Heatmap showing average log2 fold changes in cytokine levels in the effluents of three LF chips created using bulk lymphocytes from donors whose prior exposure to rabies was unknown, measured using a Luminex Multiplex Assay at various time points (4, 7, 15, 22, and 28 days post-vaccination) compared to the average levels of each cytokine found at day 1. Representative results from one donor are shown in (B)–(D) and (H), with similar outcomes observed in two donors. Data shown are mean ± SD; (C, left; D; and E) one way ANOVA test followed by Tukey’s multiple comparisons test, (C, right; and E) Mann-Whitney U test, (F and G) Welch’s t test.
    Figure Legend Snippet: Induction of LFs and anti-RABV-G IgG production by SAM-LNP1 in human LF chips (A) Schematic of the LF Chip created with monocytes and conditioned medium from the intramuscular vaccination-mimicking module created with BioRender.com . (B) Representative 3D confocal microscopic stacks showing pseudo-colored follicles (blue) and cell nuclei (green) present within extracellular matrix (ECM) gels cultured for 4 days within a perfused LF Chip when vaccinated with SAM-LNP1 in the absence or presence of IL-2 and IL-4 (SAM-LNP1 + IL-2&IL-4); scale bars, 100 μm. (C) Quantification of the number (left) and size (right) of LFs in LF chips of one donor based on immunostaining followed by confocal imaging. Each data point represents one field of view (left) or an individual follicle (right); 2 independent chips were analyzed per condition. (D) Anti-RABV-G IgG levels in effluents of no treatment LF chips or chips vaccinated with or without IL-2 and IL-4 and cultured for 14 days were detected using a cell-based assay; 3–4 independent chips were analyzed per condition. (E) Quantification of the number (left) and size (right) of LFs in LF chips from four different donors, with each color representing a different donor. Each data point corresponds to one field of view (left) or an individual follicle (right). (F) Anti-RABV-G IgG levels in effluents of LF chips. Each data point represents one chip, with different symbols indicating chips from three independent donors. (G) Anti-RABV-G IgG levels in effluents of LF chips seeded with naive B + bulk T + monocyte mixture. Each data point represents one chip, with different symbols indicating chips from three independent donors. (H) Heatmap showing average log2 fold changes in cytokine levels in the effluents of three LF chips created using bulk lymphocytes from donors whose prior exposure to rabies was unknown, measured using a Luminex Multiplex Assay at various time points (4, 7, 15, 22, and 28 days post-vaccination) compared to the average levels of each cytokine found at day 1. Representative results from one donor are shown in (B)–(D) and (H), with similar outcomes observed in two donors. Data shown are mean ± SD; (C, left; D; and E) one way ANOVA test followed by Tukey’s multiple comparisons test, (C, right; and E) Mann-Whitney U test, (F and G) Welch’s t test.

    Techniques Used: Cell Culture, Immunostaining, Imaging, Cell Based Assay, Luminex, Multiplex Assay, MANN-WHITNEY

    Related Articles

    Isolation:

    Article Title: RIG-I Stimulation Enhances the Effector Function and Proliferation of Primary Human CD8+ T Cells.
    Article Snippet: CD8+ T cells were purified from isolated PBMCs via the EasySepTM Human CD8+ T-Cell Isolation Kit (Stemcell Technologies, Vancouver, BC, Canada, #17953) through negative selection. .. These isolated cells were then cultured in RPMI 1640 medium (Thermo Fisher Scientific, Langerwehe, Germany, #11875093) containing 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, Langerwehe, Germany, #10437028), 100 U/mL penicillin, 100 μg/mL streptomycin (Thermo Fisher Scientific, Langerwehe, Germany, #15140122), and 100 U/mL human IL-2 (Miltenyi Biotec, https://doi.org/10.3390/ijms27073058 Bergisch Gladbach, Germany, #130-097-743) at 37 ◦C in a humidified atmosphere of 5% CO2. ..

    Article Title: RIG-I Stimulation Enhances the Effector Function and Proliferation of Primary Human CD8+ T Cells
    Article Snippet: CD8+ T cells were purified from isolated PBMCs via the EasySepTM Human CD8+ T-Cell Isolation Kit (Stemcell Technologies, Vancouver, BC, Canada, #17953) through negative selection. .. These isolated cells were then cultured in RPMI 1640 medium (Thermo Fisher Scientific, Langerwehe, Germany, #11875093) containing 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, Langerwehe, Germany, #10437028), 100 U/mL penicillin, 100 μg/mL streptomycin (Thermo Fisher Scientific, Langerwehe, Germany, #15140122), and 100 U/mL human IL-2 (Miltenyi Biotec, Bergisch Gladbach, Germany, #130-097-743) at 37 °C in a humidified atmosphere of 5% CO 2 . ..

    Article Title: Armored Chimeric Antigen Receptor-T Cell Therapy Targets Antigen-Heterogeneous Glioma
    Article Snippet: The remaining splenocytes were processed via magnetic-bead negative selection to isolate pan-T cells, using a Pan T Cell Isolation Kit II (Miltenyi, Cat# 130-095-130). .. The isolated pan-T cells were then activated using Mouse Dynabead T-cell Activator (ThermoFisher, Cat# 11453D) beads at a 1:1 cell to bead ratio, and cultured in RPMI 1640 with HEPES supplemented with 10% HI-FBS + 20 mM HEPES + 1 mM Sodium Pyruvate (ThermoFisher, Cat# 11360070) + 1 mL GlutaMAX TM (ThermoFisher, Cat# 35050061) + 1x Antibiotic/Antimycotic (Cytiva, Cat# SV30079.01) + 55 μM 2-Mercaptoethanol (ThermoFisher, Cat# 21985023) + 40 U/mL human IL-2 (Miltenyi, Cat# 130-097-748). ..

    Cell Culture:

    Article Title: RIG-I Stimulation Enhances the Effector Function and Proliferation of Primary Human CD8+ T Cells.
    Article Snippet: CD8+ T cells were purified from isolated PBMCs via the EasySepTM Human CD8+ T-Cell Isolation Kit (Stemcell Technologies, Vancouver, BC, Canada, #17953) through negative selection. .. These isolated cells were then cultured in RPMI 1640 medium (Thermo Fisher Scientific, Langerwehe, Germany, #11875093) containing 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, Langerwehe, Germany, #10437028), 100 U/mL penicillin, 100 μg/mL streptomycin (Thermo Fisher Scientific, Langerwehe, Germany, #15140122), and 100 U/mL human IL-2 (Miltenyi Biotec, https://doi.org/10.3390/ijms27073058 Bergisch Gladbach, Germany, #130-097-743) at 37 ◦C in a humidified atmosphere of 5% CO2. ..

    Article Title: RIG-I Stimulation Enhances the Effector Function and Proliferation of Primary Human CD8+ T Cells
    Article Snippet: CD8+ T cells were purified from isolated PBMCs via the EasySepTM Human CD8+ T-Cell Isolation Kit (Stemcell Technologies, Vancouver, BC, Canada, #17953) through negative selection. .. These isolated cells were then cultured in RPMI 1640 medium (Thermo Fisher Scientific, Langerwehe, Germany, #11875093) containing 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, Langerwehe, Germany, #10437028), 100 U/mL penicillin, 100 μg/mL streptomycin (Thermo Fisher Scientific, Langerwehe, Germany, #15140122), and 100 U/mL human IL-2 (Miltenyi Biotec, Bergisch Gladbach, Germany, #130-097-743) at 37 °C in a humidified atmosphere of 5% CO 2 . ..

    Article Title: Armored Chimeric Antigen Receptor-T Cell Therapy Targets Antigen-Heterogeneous Glioma
    Article Snippet: The remaining splenocytes were processed via magnetic-bead negative selection to isolate pan-T cells, using a Pan T Cell Isolation Kit II (Miltenyi, Cat# 130-095-130). .. The isolated pan-T cells were then activated using Mouse Dynabead T-cell Activator (ThermoFisher, Cat# 11453D) beads at a 1:1 cell to bead ratio, and cultured in RPMI 1640 with HEPES supplemented with 10% HI-FBS + 20 mM HEPES + 1 mM Sodium Pyruvate (ThermoFisher, Cat# 11360070) + 1 mL GlutaMAX TM (ThermoFisher, Cat# 35050061) + 1x Antibiotic/Antimycotic (Cytiva, Cat# SV30079.01) + 55 μM 2-Mercaptoethanol (ThermoFisher, Cat# 21985023) + 40 U/mL human IL-2 (Miltenyi, Cat# 130-097-748). ..

    Article Title: L-type voltage-gated Ca 2+ channels control T cell killing via non-canonical Hedgehog signalling
    Article Snippet: Murine CD4 + T cells were maintained at 1 × 10 6 /ml in complete IMDM media: (Gibco, Cat no. 12440061) supplemented with 5% heat-inactivated batch-tested FCS, 10 μM β-Mercaptoethanol, 100 U/ml Penicillin/Streptomycin and 40 ng/ml human IL-2 (Peprotech, Cat no. 200-02-100). .. Human CD8 + T cells were cultured at 0.25–0.4 × 10 6 cells/ml in ImmunoCult cell culture media (Stemcell Technologies, Cat no. 10981) supplemented with 100 U/ml Penicillin/Streptomycin and 100 IU/ml human IL-2 (Miltenyi, Cat no. 130-097-746). .. Human Vγ9Vδ2 + T cells were cultured in complete Vγ9Vδ2 + T cell media: RPMI supplemented with 10% heat-inactivated batch-tested FCS, 1 μM Sodium Pyruvate, 20 μM HEPES, 1x MEM Non-Essential Amino Acid Solution (Gibco, Cat no. 11140-035), 100 U/ml Penicillin/Streptomycin, 100 IU/mL human IL-2 and 120 IU/mL human IL-15 (Miltenyi, Cat no. 130-095-765).

    Article Title: BAG2 Condensates Couple Proteostasis to CD8 + T Cell Surveillance
    Article Snippet: .. Cells were cultured at 37 °C in a humidified atmosphere with 5% CO2 in RPMI supplemented with recombinant human IL-2 (30,000 U ml−1, Milteny Biotec, Cat #130-097-743). ..

    Recombinant:

    Article Title: Targeting PD-1 + T cells with chimeric antigen receptors to reduce the HIV reservoir
    Article Snippet: After 24 hours from lentiviral transduction cells were washed and cultured for the rest of the expansion in Roswell Park Memorial Institute (RPMI) medium (Gibco, Waltham, MA, USA, catalog no. 61870-010) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich, Saint-Louis, MO, USA, catalog no. F7524), 1% nonessential amino acids (NEAAs; Gibco, Grand Island, NY, USA, catalog no. 11140-050), 10 mM HEPES buffer solution (Gibco, Paisley, UK, catalog no. 15630-056), 1 mM sodium pyruvate (Gibco, Waltham, MA, USA, catalog no. 11360-039), and 1% penicillin-streptomycin. .. Medium was supplemented with recombinant human IL-2 (30 IU/ml; rhIL-2, Miltenyi Biotec, Bergisch-Gladbach, Germany, catalog no. 130-097-746) for T cells or CD4 + T cells, 100 IU/ml for CD8 + T cells when expanded alone. .. For the in vivo experiments, the T cell medium was enriched with rhIL-7 (5 ng/ml; Miltenyi Biotec, Bergisch-Gladbach, Germany, catalog no. 130-095-362), rhIL-15 (5 ng/ml; Miltenyi Biotec, Bergisch-Gladbach, Germany, catalog no. 130-095-764), and IL-2 (30 IU/ml).

    Article Title: BAG2 Condensates Couple Proteostasis to CD8 + T Cell Surveillance
    Article Snippet: .. Cells were cultured at 37 °C in a humidified atmosphere with 5% CO2 in RPMI supplemented with recombinant human IL-2 (30,000 U ml−1, Milteny Biotec, Cat #130-097-743). ..

    other:

    Article Title: Dynamic estimation of metabolic state during CAR T cell production.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies PE/Cy7 anti-CD3 (clone HIT3a) Biolegend Cat# 300316, Lot# B366496; RRID: AB_314052 BV605 anti-CD45RA clone HI100) Biolegend Cat# 304134, Lot# B346157; RRID: AB_2563814 PE anti-CCR7 (clone G043H7) Biolegend Cat# 353204, Lot# B355521; RRID: AB_10913813 PerCP/Cy5.5 anti-LAG-3 (clone 11C3C65) Biolegend Cat# 369312, Lot# B335890; RRID: AB_2629755 AF700 anti-PD-1 (clone EH12.2H7) Biolegend Cat# 329952, Lot# B351613; RRID: AB_2566364 APC/Fire 750 anti-TIM-3 (clone F38-2E2) Biolegend Cat# 345044, Lot# B359214; RRID: AB_2632856 Biological samples Human Peripheral Blood Mononuclear Cells, Frozen STEMCELL Technologies Catalog# 70025 PBMCs from anonymised adult lymphoma patients Discarded leukapheresis tubing sets SingHealth Centralized Institutional Review Board (CIRB; approval #2018/2677) Chemicals, peptides, and recombinant proteins Recombinant Human IL-2 IS, premium grade Miltenyi Biotec Cat# 130-097-748 CryoStor CS10 STEMCELL Technologies # 07930 Lipofectamine 3000 Transfection Reagent Thermo Fisher Scientific Cat# L3000-075 Bioreactor pH Adjustment Solution Merck Sigma-Aldrich Cat# B1185-1L Critical commercial assays EasySep Human T cell Isolation Kit STEMCELL Technologies Cat# 17951 Dynabeads Human T-Expander CD3/CD28 Thermo Fisher Scientific Cat# 11141D Bright-Glo TM Luciferase Assay System Promega Cat# E2610 Experimental models: Cell lines Lenti-X 293T cell Line Takara Bio Inc. Cat# 632180 Jurkat (clone E6-1; TIB-152) ATCC TIB-152 NALM6-Luc M. Birnbaum N/A Recombinant DNA pMDLg/pRRE D. Trono Addgene# 12251 pRSV-Rev D. Trono Addgene# 12253 pMD2.G D. Trono Addgene# 12259 anti-CD19 CAR-IRES-EGFP M. Birnbaum N/A Software and algorithms MBS Dashboard v1.5.5.0n Erbi Biosystems, MilliporeSigma N/A CytExpert v2.4 Beckman Coulter N/A MATLAB R2023a MathWorks N/A Code developed for metabolic rate analysis N. Suhas Jagannathan (This paper) https://doi.org/10.5281/ zenodo.17890801 e1 Cell Reports Methods 6, 101303, February 23, 2026 OPEN ACCESS Human T cell isolation, activation, transduction and expansion from healthy PBMCs T cells were isolated from human PBMCs from healthy donors (STEMCELL Technologies) using EasySep Human T cell Isolation Kit (STEMCELL Technologies) and resuspended in AIM V Medium (Thermo Fisher Scientific) supplemented with 2% human male AB serum (Merck Sigma-Aldrich) and 100 IU mL − 1 recombinant human IL-2 (Miltenyi Biotec).



    Similar Products

    95
    Multi Sciences (Lianke) Biotech Co Ltd human il-2 elisa kit
    Human Il 2 Elisa Kit, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+2/Human+IL-2+ELISA+Kit/custom%40ek102%4042628379
    Average 95 stars, based on 1 article reviews
    human il-2 elisa kit - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec part conditioned medium
    Induction of LFs and anti-RABV-G IgG production by SAM-LNP1 in human LF chips (A) Schematic of the LF Chip created with monocytes and <t>conditioned</t> medium from the intramuscular vaccination-mimicking module created with BioRender.com . (B) Representative 3D confocal microscopic stacks showing pseudo-colored follicles (blue) and cell nuclei (green) present within extracellular matrix (ECM) gels cultured for 4 days within a perfused LF Chip when vaccinated with SAM-LNP1 in the absence or presence of IL-2 and IL-4 (SAM-LNP1 + IL-2&IL-4); scale bars, 100 μm. (C) Quantification of the number (left) and size (right) of LFs in LF chips of one donor based on immunostaining followed by confocal imaging. Each data point represents one field of view (left) or an individual follicle (right); 2 independent chips were analyzed per condition. (D) Anti-RABV-G IgG levels in effluents of no treatment LF chips or chips vaccinated with or without IL-2 and IL-4 and cultured for 14 days were detected using a cell-based assay; 3–4 independent chips were analyzed per condition. (E) Quantification of the number (left) and size (right) of LFs in LF chips from four different donors, with each color representing a different donor. Each data point corresponds to one field of view (left) or an individual follicle (right). (F) Anti-RABV-G IgG levels in effluents of LF chips. Each data point represents one chip, with different symbols indicating chips from three independent donors. (G) Anti-RABV-G IgG levels in effluents of LF chips seeded with naive B + bulk T + monocyte mixture. Each data point represents one chip, with different symbols indicating chips from three independent donors. (H) Heatmap showing average log2 fold changes in cytokine levels in the effluents of three LF chips created using bulk lymphocytes from donors whose prior exposure to rabies was unknown, measured using a Luminex Multiplex Assay at various time points (4, 7, 15, 22, and 28 days post-vaccination) compared to the average levels of each cytokine found at day 1. Representative results from one donor are shown in (B)–(D) and (H), with similar outcomes observed in two donors. Data shown are mean ± SD; (C, left; D; and E) one way ANOVA test followed by Tukey’s multiple comparisons test, (C, right; and E) Mann-Whitney U test, (F and G) Welch’s t test.
    Part Conditioned Medium, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+2/Human+IL-2+IS%2C+research+grade/pmc13314794-290-18-34
    Average 96 stars, based on 1 article reviews
    part conditioned medium - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    93
    MedChemExpress recombinant human il 2 protein
    Induction of LFs and anti-RABV-G IgG production by SAM-LNP1 in human LF chips (A) Schematic of the LF Chip created with monocytes and <t>conditioned</t> medium from the intramuscular vaccination-mimicking module created with BioRender.com . (B) Representative 3D confocal microscopic stacks showing pseudo-colored follicles (blue) and cell nuclei (green) present within extracellular matrix (ECM) gels cultured for 4 days within a perfused LF Chip when vaccinated with SAM-LNP1 in the absence or presence of IL-2 and IL-4 (SAM-LNP1 + IL-2&IL-4); scale bars, 100 μm. (C) Quantification of the number (left) and size (right) of LFs in LF chips of one donor based on immunostaining followed by confocal imaging. Each data point represents one field of view (left) or an individual follicle (right); 2 independent chips were analyzed per condition. (D) Anti-RABV-G IgG levels in effluents of no treatment LF chips or chips vaccinated with or without IL-2 and IL-4 and cultured for 14 days were detected using a cell-based assay; 3–4 independent chips were analyzed per condition. (E) Quantification of the number (left) and size (right) of LFs in LF chips from four different donors, with each color representing a different donor. Each data point corresponds to one field of view (left) or an individual follicle (right). (F) Anti-RABV-G IgG levels in effluents of LF chips. Each data point represents one chip, with different symbols indicating chips from three independent donors. (G) Anti-RABV-G IgG levels in effluents of LF chips seeded with naive B + bulk T + monocyte mixture. Each data point represents one chip, with different symbols indicating chips from three independent donors. (H) Heatmap showing average log2 fold changes in cytokine levels in the effluents of three LF chips created using bulk lymphocytes from donors whose prior exposure to rabies was unknown, measured using a Luminex Multiplex Assay at various time points (4, 7, 15, 22, and 28 days post-vaccination) compared to the average levels of each cytokine found at day 1. Representative results from one donor are shown in (B)–(D) and (H), with similar outcomes observed in two donors. Data shown are mean ± SD; (C, left; D; and E) one way ANOVA test followed by Tukey’s multiple comparisons test, (C, right; and E) Mann-Whitney U test, (F and G) Welch’s t test.
    Recombinant Human Il 2 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+2/IL-2%2C+Human/pmc13389675-136-27-31
    Average 93 stars, based on 1 article reviews
    recombinant human il 2 protein - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec il 2
    Induction of LFs and anti-RABV-G IgG production by SAM-LNP1 in human LF chips (A) Schematic of the LF Chip created with monocytes and <t>conditioned</t> medium from the intramuscular vaccination-mimicking module created with BioRender.com . (B) Representative 3D confocal microscopic stacks showing pseudo-colored follicles (blue) and cell nuclei (green) present within extracellular matrix (ECM) gels cultured for 4 days within a perfused LF Chip when vaccinated with SAM-LNP1 in the absence or presence of IL-2 and IL-4 (SAM-LNP1 + IL-2&IL-4); scale bars, 100 μm. (C) Quantification of the number (left) and size (right) of LFs in LF chips of one donor based on immunostaining followed by confocal imaging. Each data point represents one field of view (left) or an individual follicle (right); 2 independent chips were analyzed per condition. (D) Anti-RABV-G IgG levels in effluents of no treatment LF chips or chips vaccinated with or without IL-2 and IL-4 and cultured for 14 days were detected using a cell-based assay; 3–4 independent chips were analyzed per condition. (E) Quantification of the number (left) and size (right) of LFs in LF chips from four different donors, with each color representing a different donor. Each data point corresponds to one field of view (left) or an individual follicle (right). (F) Anti-RABV-G IgG levels in effluents of LF chips. Each data point represents one chip, with different symbols indicating chips from three independent donors. (G) Anti-RABV-G IgG levels in effluents of LF chips seeded with naive B + bulk T + monocyte mixture. Each data point represents one chip, with different symbols indicating chips from three independent donors. (H) Heatmap showing average log2 fold changes in cytokine levels in the effluents of three LF chips created using bulk lymphocytes from donors whose prior exposure to rabies was unknown, measured using a Luminex Multiplex Assay at various time points (4, 7, 15, 22, and 28 days post-vaccination) compared to the average levels of each cytokine found at day 1. Representative results from one donor are shown in (B)–(D) and (H), with similar outcomes observed in two donors. Data shown are mean ± SD; (C, left; D; and E) one way ANOVA test followed by Tukey’s multiple comparisons test, (C, right; and E) Mann-Whitney U test, (F and G) Welch’s t test.
    Il 2, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+2/Human+IL-2+IS%2C+research+grade/pmc13261076-65-0-2
    Average 96 stars, based on 1 article reviews
    il 2 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec recombinant human il 2
    Induction of LFs and anti-RABV-G IgG production by SAM-LNP1 in human LF chips (A) Schematic of the LF Chip created with monocytes and <t>conditioned</t> medium from the intramuscular vaccination-mimicking module created with BioRender.com . (B) Representative 3D confocal microscopic stacks showing pseudo-colored follicles (blue) and cell nuclei (green) present within extracellular matrix (ECM) gels cultured for 4 days within a perfused LF Chip when vaccinated with SAM-LNP1 in the absence or presence of IL-2 and IL-4 (SAM-LNP1 + IL-2&IL-4); scale bars, 100 μm. (C) Quantification of the number (left) and size (right) of LFs in LF chips of one donor based on immunostaining followed by confocal imaging. Each data point represents one field of view (left) or an individual follicle (right); 2 independent chips were analyzed per condition. (D) Anti-RABV-G IgG levels in effluents of no treatment LF chips or chips vaccinated with or without IL-2 and IL-4 and cultured for 14 days were detected using a cell-based assay; 3–4 independent chips were analyzed per condition. (E) Quantification of the number (left) and size (right) of LFs in LF chips from four different donors, with each color representing a different donor. Each data point corresponds to one field of view (left) or an individual follicle (right). (F) Anti-RABV-G IgG levels in effluents of LF chips. Each data point represents one chip, with different symbols indicating chips from three independent donors. (G) Anti-RABV-G IgG levels in effluents of LF chips seeded with naive B + bulk T + monocyte mixture. Each data point represents one chip, with different symbols indicating chips from three independent donors. (H) Heatmap showing average log2 fold changes in cytokine levels in the effluents of three LF chips created using bulk lymphocytes from donors whose prior exposure to rabies was unknown, measured using a Luminex Multiplex Assay at various time points (4, 7, 15, 22, and 28 days post-vaccination) compared to the average levels of each cytokine found at day 1. Representative results from one donor are shown in (B)–(D) and (H), with similar outcomes observed in two donors. Data shown are mean ± SD; (C, left; D; and E) one way ANOVA test followed by Tukey’s multiple comparisons test, (C, right; and E) Mann-Whitney U test, (F and G) Welch’s t test.
    Recombinant Human Il 2, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+2/Human+IL-2+IS%2C+research+grade/pm42447864-743-33-36
    Average 96 stars, based on 1 article reviews
    recombinant human il 2 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec il 1β miltenyi biotec
    Induction of LFs and anti-RABV-G IgG production by SAM-LNP1 in human LF chips (A) Schematic of the LF Chip created with monocytes and <t>conditioned</t> medium from the intramuscular vaccination-mimicking module created with BioRender.com . (B) Representative 3D confocal microscopic stacks showing pseudo-colored follicles (blue) and cell nuclei (green) present within extracellular matrix (ECM) gels cultured for 4 days within a perfused LF Chip when vaccinated with SAM-LNP1 in the absence or presence of IL-2 and IL-4 (SAM-LNP1 + IL-2&IL-4); scale bars, 100 μm. (C) Quantification of the number (left) and size (right) of LFs in LF chips of one donor based on immunostaining followed by confocal imaging. Each data point represents one field of view (left) or an individual follicle (right); 2 independent chips were analyzed per condition. (D) Anti-RABV-G IgG levels in effluents of no treatment LF chips or chips vaccinated with or without IL-2 and IL-4 and cultured for 14 days were detected using a cell-based assay; 3–4 independent chips were analyzed per condition. (E) Quantification of the number (left) and size (right) of LFs in LF chips from four different donors, with each color representing a different donor. Each data point corresponds to one field of view (left) or an individual follicle (right). (F) Anti-RABV-G IgG levels in effluents of LF chips. Each data point represents one chip, with different symbols indicating chips from three independent donors. (G) Anti-RABV-G IgG levels in effluents of LF chips seeded with naive B + bulk T + monocyte mixture. Each data point represents one chip, with different symbols indicating chips from three independent donors. (H) Heatmap showing average log2 fold changes in cytokine levels in the effluents of three LF chips created using bulk lymphocytes from donors whose prior exposure to rabies was unknown, measured using a Luminex Multiplex Assay at various time points (4, 7, 15, 22, and 28 days post-vaccination) compared to the average levels of each cytokine found at day 1. Representative results from one donor are shown in (B)–(D) and (H), with similar outcomes observed in two donors. Data shown are mean ± SD; (C, left; D; and E) one way ANOVA test followed by Tukey’s multiple comparisons test, (C, right; and E) Mann-Whitney U test, (F and G) Welch’s t test.
    Il 1β Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+2/Human+IL-2+IS%2C+premium+grade/10__1016_slash_j__isci__2026__116736-639-132-133
    Average 96 stars, based on 1 article reviews
    il 1β miltenyi biotec - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec medium
    Induction of LFs and anti-RABV-G IgG production by SAM-LNP1 in human LF chips (A) Schematic of the LF Chip created with monocytes and <t>conditioned</t> medium from the intramuscular vaccination-mimicking module created with BioRender.com . (B) Representative 3D confocal microscopic stacks showing pseudo-colored follicles (blue) and cell nuclei (green) present within extracellular matrix (ECM) gels cultured for 4 days within a perfused LF Chip when vaccinated with SAM-LNP1 in the absence or presence of IL-2 and IL-4 (SAM-LNP1 + IL-2&IL-4); scale bars, 100 μm. (C) Quantification of the number (left) and size (right) of LFs in LF chips of one donor based on immunostaining followed by confocal imaging. Each data point represents one field of view (left) or an individual follicle (right); 2 independent chips were analyzed per condition. (D) Anti-RABV-G IgG levels in effluents of no treatment LF chips or chips vaccinated with or without IL-2 and IL-4 and cultured for 14 days were detected using a cell-based assay; 3–4 independent chips were analyzed per condition. (E) Quantification of the number (left) and size (right) of LFs in LF chips from four different donors, with each color representing a different donor. Each data point corresponds to one field of view (left) or an individual follicle (right). (F) Anti-RABV-G IgG levels in effluents of LF chips. Each data point represents one chip, with different symbols indicating chips from three independent donors. (G) Anti-RABV-G IgG levels in effluents of LF chips seeded with naive B + bulk T + monocyte mixture. Each data point represents one chip, with different symbols indicating chips from three independent donors. (H) Heatmap showing average log2 fold changes in cytokine levels in the effluents of three LF chips created using bulk lymphocytes from donors whose prior exposure to rabies was unknown, measured using a Luminex Multiplex Assay at various time points (4, 7, 15, 22, and 28 days post-vaccination) compared to the average levels of each cytokine found at day 1. Representative results from one donor are shown in (B)–(D) and (H), with similar outcomes observed in two donors. Data shown are mean ± SD; (C, left; D; and E) one way ANOVA test followed by Tukey’s multiple comparisons test, (C, right; and E) Mann-Whitney U test, (F and G) Welch’s t test.
    Medium, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+2/MACS+GMP+Recombinant+Human+IL-2/us12668640-299-2-10
    Average 94 stars, based on 1 article reviews
    medium - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    Image Search Results


    Induction of LFs and anti-RABV-G IgG production by SAM-LNP1 in human LF chips (A) Schematic of the LF Chip created with monocytes and conditioned medium from the intramuscular vaccination-mimicking module created with BioRender.com . (B) Representative 3D confocal microscopic stacks showing pseudo-colored follicles (blue) and cell nuclei (green) present within extracellular matrix (ECM) gels cultured for 4 days within a perfused LF Chip when vaccinated with SAM-LNP1 in the absence or presence of IL-2 and IL-4 (SAM-LNP1 + IL-2&IL-4); scale bars, 100 μm. (C) Quantification of the number (left) and size (right) of LFs in LF chips of one donor based on immunostaining followed by confocal imaging. Each data point represents one field of view (left) or an individual follicle (right); 2 independent chips were analyzed per condition. (D) Anti-RABV-G IgG levels in effluents of no treatment LF chips or chips vaccinated with or without IL-2 and IL-4 and cultured for 14 days were detected using a cell-based assay; 3–4 independent chips were analyzed per condition. (E) Quantification of the number (left) and size (right) of LFs in LF chips from four different donors, with each color representing a different donor. Each data point corresponds to one field of view (left) or an individual follicle (right). (F) Anti-RABV-G IgG levels in effluents of LF chips. Each data point represents one chip, with different symbols indicating chips from three independent donors. (G) Anti-RABV-G IgG levels in effluents of LF chips seeded with naive B + bulk T + monocyte mixture. Each data point represents one chip, with different symbols indicating chips from three independent donors. (H) Heatmap showing average log2 fold changes in cytokine levels in the effluents of three LF chips created using bulk lymphocytes from donors whose prior exposure to rabies was unknown, measured using a Luminex Multiplex Assay at various time points (4, 7, 15, 22, and 28 days post-vaccination) compared to the average levels of each cytokine found at day 1. Representative results from one donor are shown in (B)–(D) and (H), with similar outcomes observed in two donors. Data shown are mean ± SD; (C, left; D; and E) one way ANOVA test followed by Tukey’s multiple comparisons test, (C, right; and E) Mann-Whitney U test, (F and G) Welch’s t test.

    Journal: iScience

    Article Title: In vitro recapitulation of intramuscular mRNA vaccination with naive and recall antigens using a human lymphoid follicle chip platform

    doi: 10.1016/j.isci.2026.116416

    Figure Lengend Snippet: Induction of LFs and anti-RABV-G IgG production by SAM-LNP1 in human LF chips (A) Schematic of the LF Chip created with monocytes and conditioned medium from the intramuscular vaccination-mimicking module created with BioRender.com . (B) Representative 3D confocal microscopic stacks showing pseudo-colored follicles (blue) and cell nuclei (green) present within extracellular matrix (ECM) gels cultured for 4 days within a perfused LF Chip when vaccinated with SAM-LNP1 in the absence or presence of IL-2 and IL-4 (SAM-LNP1 + IL-2&IL-4); scale bars, 100 μm. (C) Quantification of the number (left) and size (right) of LFs in LF chips of one donor based on immunostaining followed by confocal imaging. Each data point represents one field of view (left) or an individual follicle (right); 2 independent chips were analyzed per condition. (D) Anti-RABV-G IgG levels in effluents of no treatment LF chips or chips vaccinated with or without IL-2 and IL-4 and cultured for 14 days were detected using a cell-based assay; 3–4 independent chips were analyzed per condition. (E) Quantification of the number (left) and size (right) of LFs in LF chips from four different donors, with each color representing a different donor. Each data point corresponds to one field of view (left) or an individual follicle (right). (F) Anti-RABV-G IgG levels in effluents of LF chips. Each data point represents one chip, with different symbols indicating chips from three independent donors. (G) Anti-RABV-G IgG levels in effluents of LF chips seeded with naive B + bulk T + monocyte mixture. Each data point represents one chip, with different symbols indicating chips from three independent donors. (H) Heatmap showing average log2 fold changes in cytokine levels in the effluents of three LF chips created using bulk lymphocytes from donors whose prior exposure to rabies was unknown, measured using a Luminex Multiplex Assay at various time points (4, 7, 15, 22, and 28 days post-vaccination) compared to the average levels of each cytokine found at day 1. Representative results from one donor are shown in (B)–(D) and (H), with similar outcomes observed in two donors. Data shown are mean ± SD; (C, left; D; and E) one way ANOVA test followed by Tukey’s multiple comparisons test, (C, right; and E) Mann-Whitney U test, (F and G) Welch’s t test.

    Article Snippet: After allowing the matrix to gel for 30 min at 37°C, the top channel was filled with 1 part conditioned medium from the 2D intramuscular module, and 2 parts fresh medium supplemented with IL-2 (Mitenyi Biotec, 130-097-742) and IL-4 (Mitenyi Biotec, 130-093-922) for experiments with RABV-G mRNA vaccines.

    Techniques: Cell Culture, Immunostaining, Imaging, Cell Based Assay, Luminex, Multiplex Assay, MANN-WHITNEY